PG

Procter & Gamble Health LtdNSE PGHL Stock Report

Last reporting period 30 Jun, 2024

Updated 11 Nov, 2024

Last price

Market cap $B

0.805

Micro

Exchange

XNSE - National Stock Exchange Of India

PGHL.NS Stock Analysis

PG

Neutral

Based on Eyestock quantitative analysis, PGHL.NS`s fundamental data and valuation indicate an investment grade of Neutral at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

117/100

High score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-8.6 %

Overvalued

Market cap $B

0.805

Dividend yield

5.42 %

Shares outstanding

16.599 B

Procter & Gamble Health Ltd. engages in the manufacture and marketing of pharmaceuticals products. The company is headquartered in Mumbai, Maharashtra and currently employs 1,407 full-time employees. The firm is engaged in the manufacturing and marketing of over-the-counter products, vitamins, minerals, and supplements products for a healthy lifestyle. The Company’s brands include Cosome, Evion, Neurobion, Seven Seas, Nasivion, Polybion, and Livogen. Cosome is a medicine which is used to help relieve dry coughs and related congestion symptoms. Evion is a Vitamin E capsules. The Evion range has different variants with different levels of Vitamin E, such as Evion 400, Evion 200, and Evion 600. Neurobion offers a range of neurotropic B-Vitamins which are a combination to help treat nerve damage and regenerate the nerves to relieve symptoms. Nasivion Classic Nasal Spray starts working on a blocked nose in 25 seconds. Polybion is a brand that helps with release and hence supports an active life.

View Section: Eyestock Rating